Events

UK Bioscience Forum w/ Gareth Jones & Peju Oshisanya

Intellectual Property in AI and data technologies

11:45am | 14 October 2020

The competing demands of data creation, data protection and data provision and acquisition pull data IP practice in different ways. How can we manage these competing demands to produce a result that is ultimately most beneficial for patients and the sector?

Speakers:

  • Gareth Jones, VP Intellectual Property at BenevolentAI
  • Dr Nicola Baker-Munton, Chief Executive Officer at Statagem
  • Joe Foster, COO at Mogrify
  • Tim Hoctor, Vice President of Global Professional Services at Elsevier
  • Jule Sigall, Associate General Counsel, Open Innovation, IP Group at Microsoft

→ Register here

Diversity in data for drug discovery and clinical applications

11:45am | 14 October 2020

A lack of diversity in clinical datasets is a known problem for the life sciences industry, and one that must be addressed. In this session, we will discuss what different organisations are doing to address this, and share lessons they have learned from their experiences.

Speakers:

  • Peju Oshisanya MSc, BSc (HONS), Director, Clinical Programme Leader at BenevolentAI
  • Maria Chatzou Dunford, CEO and Co-Founder at Lifebit Biotech
  • Annette Jack, Founder at Egality
  • Dr Jason Mellad, CEO at Start Codon
  • Umang Patel, Clinical Director, Babylon

→ Register here


Peju Oshisanya

Clinical Drug Development Leader & Data Diversity Advocate at BenevolentAI

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Gareth Jones

VP Intellectual Property

Gareth Jones is one of the the world's leading intellectual property strategists (IAM Strategy 300). At BenevolentAI he is responsible for IP activities including strategy, portfolio development, competitive intelligence, fundraising and M&A diligence, patent and data licensing, and collaborations. Gareth has worked at IBM, Vodafone, Microsoft, and also at tech startup SwiftKey where he built and scaled IP operations for one of the largest UK tech exits of 2015/2016


More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021